Results 41 to 50 of about 7,553 (206)

The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs

Haematologica, 2019
Tyrosine kinases have been implicated in promoting tumorigenesis of several human cancers. Exploiting these vulnerabilities has been shown to be an effective anti-tumor strategy as demonstrated for example by the Bruton's tyrosine kinase (BTK) inhibitor,
Debora Soncini, Stefania Orecchioni, Samantha Ruberti, Paola Minetto, Claudia Martinuzzi, Luca Agnelli, Katia Todoerti, Antonia Cagnetta, Maurizio Miglino, Marino Clavio, Paola Contini, Riccardo Varaldo, Micaela Bergamaschi, Fabio Guolo, Mario Passalacqua, Alessio Nencioni, Fiammetta Monacelli, Marco Gobbi, Antonino Neri, Giovanni Abbadessa, Sudharshan Eathiraj, Brian Schwartz, Francesco Bertolini, Roberto M. Lemoli, Michele Cea   +24 more
doaj   +1 more source

Ibrutinib for B cell malignancies [PDF]

, 2014
Research over the role of Bruton’s agammaglobulinemia tyrosine kinase (BTK) in B-lymphocyte development, differentiation, signaling and survival has led to better understanding of the pathogenesis of B-cell malignancies.
Aileen Novero, Delong Liu, George Dous, Pavan M Ravella, Yamei Chen   +4 more
core   +1 more source

Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry

Nature Communications, 2020
PROTACs have emerged as promising therapeutic agents but their cellular uptake is often inefficient. Here, the authors show that reversible covalent warhead chemistry improves PROTAC intracellular accumulation and target engagement, and develop a dual ...
Wen-Hao Guo, Xiaoli Qi, Xin Yu, Yang Liu, Chan-I Chung, Fang Bai, Xingcheng Lin, Dong Lu, Lingfei Wang, Jianwei Chen, Lynn Hsiao Su, Krystle J. Nomie, Feng Li, Meng C. Wang, Xiaokun Shu, José N. Onuchic, Jennifer A. Woyach, Michael L. Wang, Jin Wang   +18 more
doaj   +1 more source

Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. [PDF]

, 2014
Ofatumumab is a humanized anti-CD20 monoclonal antibody that has been approved by the FDA for the treatment of patients with chronic lymphocytic leukemia. We conducted a phase II single-arm study at a single center.
Almahasnah, E, Carvajal, T, Castro, JE, Chang, J, Choi, MY, James, DF, Kipps, TJ   +6 more
core   +3 more sources

Bruton's tyrosine kinase: oncotarget in myeloma

Oncotarget, 2012
Our findings therefore provide a strong rationale for investigating Btk inhibitors in MM and WM to target both tumor cells and their supporting BM microenvironment and thereby both suppress tumor cell growth and abrogate MM-induced bone disease.
Yu-Tzu, Tai, Kenneth C, Anderson
openaire   +3 more sources

Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data

Turkish Journal of Hematology, 2021
Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age +- standard deviation:
Anıl Tombak, Funda Pepedil Tanrıkulu, Salih Sertaç Durusoy, Hüseyin Derya Dinçyürek, Emin Kaya, Elif Gülsüm Ümit, İrfan Yavaşoğlu, Özgür Mehtap, Burak Deveci, Mehmet Ali Özcan, Hatice Terzi, Müfide Okay, Nilgün Sayınalp, Mehmet Yılmaz, Vahap Okan, Alperen Kızıklı, Ömer Özcan, Güven Çetin, Sinan Demircioğlu, İsmet Aydoğdu, Güray Saydam, Eren Arslan Davulcu, Gül İlhan, Mehmet Ali Uçar, Gülsüm Özet, Seval Akpınar, Burhan Turgut, İlhami Berber, Erdal Kurtoğlu, Mehmet Sönmez, Derya Selim Batur, Rahşan Yıldırım, Vildan Özkocaman, Ahmet Kürşad Güneş, Birsen Sahip, Şehmus Ertop, Olga Meltem Akay, Abdülkadir Baştürk, Mehmet Hilmi Doğu, Aydan Akdeniz, Ali Ünal, Ahmet Seyhanlı, Emel Gürkan, Demet Çekdemir, Burhan Ferhanoğlu   +44 more
doaj   +1 more source

Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells [PDF]

, 2015
Background: Roughly 80% of patients with acute myeloid leukaemia have high activity of Bruton's tyrosine-kinase (BTK) in their blast cells compared with normal haemopoietic cells, rendering the cells sensitive to the oral BTK inhibitor ibrutinib in vitro.
Advani, Bendall, Burger, Burnett, Byrd, Chung, Dasmahapatra, de Rooij, de Weers, Dohner, Dos Santos, Dubovsky, Döhner, Fiedler, Fiedler, Gao, Gu, Hahn, Honda, Horwood, Ikeda, Ito, Juliusson, Kim, Koketsu, Kvinlaug, Ma, Matsunaga, Meng, Miettinen, Oellerich, Rushworth, Rushworth, Rushworth, Rushworth, Rushworth, Schmidt, Sivina, Sun, Tai, Tomasson, Wang, Wang, Welch   +43 more
core   +1 more source

Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib

Case Reports in Infectious Diseases, 2016
Cryptococcus is a unique environmental fungus that can cause disease most often in immunocompromised individuals with defective cell-mediated immunity. Chronic lymphocytic leukemia (CLL) is not known to be a risk factor for cryptococcal disease although ...
Koh Okamoto, Laurie A. Proia, Patricia L. Demarais   +2 more
doaj   +1 more source

A distinct role for B1b lymphocytes in T cell-independent immunity [PDF]

, 2008
Pathogenesis of infectious disease is not only determined by the virulence of the microbe but also by the immune status of the host. Vaccination is the most effective means to control infectious diseases.
A Faili, A Scorpio, A Vink, A Zandvoort, A Zandvoort, AA Belperron, AB Kantor, AB Kantor, AB Satterthwaite, AF Ochsenbein, AG Barbour, AG Barbour, AM Stall, C Janeway, CA Jefferies, CA Jefferies, CD Landers, CG Vinuesa, CG Vinuesa de, CM Snapper, D Cadavid, D Tarlinton, DD Pinschewer, DE Briles, DE Mosier, DE Mosier, DF Amsbaugh, DF Kelly, DF Kelly, E Fikrig, E Montecino-Rodriguez, E Montecino-Rodriguez, E Szomolanyi-Tsuda, E Szomolanyi-Tsuda, E Szomolanyi-Tsuda, EA Kurt-Jones, EA Leadbetter, ES Shang, F Martin, F Martin, F Martin, G Muller, GB Lesinski, H Toyama, HC Selinka, I Scher, IC MacLennan, J Andersson, J Chinen, J Couderc, JA Gebbia, JC Garcia-Monco, JD Thomas, JR Hiernaux, JW Tung, K Takeda, KM Ansel, KM Haas, KM Toellner, KR Alugupalli, KR Alugupalli, KR Alugupalli, KR Alugupalli, KR Alugupalli, KR Alugupalli, L Knoops, LJ McHeyzer-Williams, M Balasz, M Boes, M Muramatsu, M Schnare, M Yokota, MA Breukels, MC Hsu, MG McHeyzer-Williams, MS Cabatingan, N Maizels, N Maizels, N Watanabe, NL Bernasconi, NW Schroder, P Dullforce, PM Southern Jr, PW Yu, Q Vos, R Berland, R Guinamard, R Malley, RB Corley, RH Carter, RH Carter, RL Chelvarajan, RL Chelvarajan, RL Chelvarajan, RL Chelvarajan, RL Chelvarajan, RM Zinkernagel, RT Woodland, RT Woodland, S Bondada, S Fagarasan, S Kruetzmann, S Weller, SA Ha, SE Connolly, SE Connolly, SH Feng, SR Yan, SR Yan, T Fehr, T Kawai, T Mizuno, T Mizuno, TL Carvalho, TT Wang, TV Obukhanych, UC Tornberg, UE Hopken, W Ellmeier, WN Khan, WN Khan, Y Arimitsu, Y Chong, Y Nagai   +123 more
core   +2 more sources

Characterization of the effects of BTK inhibition and monocyte-produced IL-8 on the hematopoietic stem cell niche [PDF]

, 2020
Hematopoietic stem and progenitor cells (HSPCs) are multipotent stem cells that give rise to all blood cell lineages. During early zebrafish development, HSPCs interact closely with endothelial cells in an endothelial niche known as the Caudal ...
Belardo, Alexander
core